Therefore, it can be inferred that BRCAness pancreatic cancer cells will not be able to repair HR deficiency; moreover, under the action of PARP inhibitors, the defective cells eventually succumb to synthetic lethality, and the sensitization of PARP-1 inhibitors will be beneficial in cancer treatment that is not dependent on the HR pathway. Here, PARP1 is linked to familial pancreatic carcinoma.